| Study | Sample Size | Tumor Type | Duration of Follow-Up | Number (%) with Cataract at End of Follow-Up | Predictors of Cataract after Treatment |
| Collaborative Ocular Melanoma Study Group 2007 [46] | 532 patients | Choroidal melanoma randomized to iodine-125 brachytherapy | 5 years | 362/568 (68%) with cataract at 5 years, 49 (9%) with cataract surgery | Radiation dose |
| Sagoo et al. 2007 [10] | 37 patients | Circumpapillary choroidal melanoma | Mean 52 months, median 46 months | 10/37 (27.0%) | -- |
| Sagoo et al. 2008 [11] | 141 patients | Juxtapapillary choroidal melanoma overhanging optic disc | Mean 56 months | 66/141 (46.8%) | -- |
| Correa et al. 2009 [43] | 120 patients | Choroidal melanoma treated with iodine-125 brachytherapy | -- | 31.6% | -- |
| Gunduz et al. 2010 [12] | 24 patients | Choroidal melanoma treated with ruthenium brachytherapy alone | -- | 2/24 (8.3%) | -- |
| Finger et al. 2011 [47] | 208 phakic patients | Uveal melanoma treated with palladium 103 | Mean 39.8 months | 76/282 (27.0%) | Age, higher radiation dose |
| Newman et al. 2011 [15] | 50 patients | Subfoveal choroidal melanomas with ≥6 months of follow-up | Median 54 months | 22% of 46 patients | -- |
| Finger et al. 2012 [16] | 24 patients | Choroidal melanomas within 1.5 mm of optic disc treated with slotted radiotherapy | Mean 23 months | 1/18 (5.5%) | -- |
| Berry et al. 2013 [17] | 82 patients | Medium sized choroidal melanomas | Median 46.8 months | 26/82 (31.7%) | -- |
| Marconi et al. 2013 [31] | 94 patients | Choroidal melanoma treated with ruthenium brachytherapy | Median 39 months | 16% | -- |
| Krema et al. 2013 [38] | 30 patients | Posterior tumor margin 0 - 2.5 mm from optic disc |
| 62% | -- |
| Semenova et al. 2014 [20] | 47 patients | T3 or T4 sized choroidal melanomas treated with palladium brachytherapy | Median 47 months | 16/47 (36%) | -- |